MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immune-based Therapies

ERS/ESTS/EACTS/ESTRO Guidelines for the Management of Malignant Pleural Mesothelioma

European Journal of Cardiothoracic Surgery 2020 May 25 [Link] Isabelle Opitz, Arnaud Scherpereel, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau, Philippe Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen, Charlotte De Bondt, Dirk De Ruysscher, Valerie Durieux, Corinne Faivre-Finn, Dean A Fennell, Francoise Galateau-Salle, Laurent Greillier, Mir Ali Hoda, Walter Klepetko, Aude Lacourt, Phil McElnay, […]

Comments Off on ERS/ESTS/EACTS/ESTRO Guidelines for the Management of Malignant Pleural Mesothelioma

Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.

Cells 2020 April 20 [Link] Nishinaga Y, Sato K, Yasui H, Taki S, Takahashi K, Shimizu M, Endo R, Koike C, Kuramoto N, Nakamura S, Fukui T, Yukawa H, Baba Y, K Kaneko M, Chen-Yoshikawa TF, Kobayashi H, Kato Y, Hasegawa Y Abstract Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. […]

Comments Off on Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.

Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy.

Archives of Endocrinology 2020 April 6 [Link] Brilli L, Calabrò L, Campanile M, Pilli T, Agostinis C, Cerase A, Maio M, Castagna M Abstract Checkpoint inhibitors have substantially improved the prognosis for patients with advanced malignancy. Treatment with immunomodulants has the ability to reactivate the immune system against tumor cells, but can also trigger the […]

Comments Off on Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy.

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

Frontiers in Oncology 2020 March 12 [Link] Cantini L, Hassan R, Sterman DH, Aerts JGJV Abstract Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment resistant neoplasm with low survival rates. In the last years we assisted to an exponential growth in the appreciation of mesothelioma pathobiology, leading several new treatments to be […]

Comments Off on Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

Immunotherapy in Malignant Pleural Mesothelioma.

Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most […]

Comments Off on Immunotherapy in Malignant Pleural Mesothelioma.

Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma.

Cancers 2020 February 27 [Link] Trempolec N, Doix B, Degavre C, Brusa D, Bouzin C, Riant O, Feron O Abstract The potential of dendritic cell (DC)-based immunotherapy to treat cancer is, nowadays, well documented. Still, the clinical success of immune checkpoint inhibitors has dampened the interest in anticancer DC vaccination. For highly life-threatening tumors that […]

Comments Off on Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma.

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Annals of Oncology 2020 January 16 [Link] Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Abstract BACKGROUND: Systemic second- […]

Comments Off on Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model.

Frontiers in Immunology 2020 January 10 [Link] Hope JL, Spantidea PI, Kiernan CH, Stairiker CJ, Rijsbergen LC, van Meurs M, Brouwers-Haspels I, Mueller YM, Nelson DJ, Bradley LM, Aerts JGJV, Katsikis PD Abstract The immune system, and in particular, cytotoxic CD8+ T cells (CTLs), plays a vital part in the prevention and elimination of tumors. In […]

Comments Off on Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model.

FREQUENT HOMOZYGOUS DELETIONS OF TYPE I INTERFERON GENES IN PLEURAL MESOTHELIOMA CONFER SENSITIVITY TO ONCOLYTIC MEASLES VIRUS.

Journal of Thoracic Oncology 2020 January 13 [Link] Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer PJ, Minvielle S, Quetel L, Meiller C, Jean D, Fradin D, Bennouna J, Magnan A, Cellerin L, Tangy F, Grégoire M, Fonteneau JF Abstract Oncolytic immunotherapy is based on the […]

Comments Off on FREQUENT HOMOZYGOUS DELETIONS OF TYPE I INTERFERON GENES IN PLEURAL MESOTHELIOMA CONFER SENSITIVITY TO ONCOLYTIC MEASLES VIRUS.

Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.

Oncotarget 2019 November 5 [Link] Donnenberg AD, Luketich JD, Donnenberg VS Abstract INTRODUCTION: We compared the secretome of metastatic (non-small cell lung cancer (NSCLC)) and primary (mesothelioma) malignant pleural effusions, benign effusions and the published plasma profile of patients receiving chimeric antigen receptor T cells (CAR-T), to determine factors unique to neoplasia in pleural effusion […]

Comments Off on Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.